The research company Hamlet Biopharma introduces a supplementary subscription period for warrants of series TO5B. It runs March 16–23, 2026 and will be at the existing subscription price of SEK 6 per share. The company describes the change as technical and administrative and states that the options’ financial terms are not affected. The previous subscription period of July 20–31 also remains. At full subscription, dilution is estimated at approximately 10 percent.